Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.

Lung Cancer

Volumn 89, Issue 3, 2015, Pages 294-300

  Kumar, Gayathri ^a   Woods, Beth ^a   Hess, Lisa M ^b   Treat, Joseph ^b   Boye, Mark E ^b   Bryden, Peter ^c   Winfree, Katherine B ^b  

^a ICON PLC   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Comparative effectiveness; Cost effectiveness; First line therapy; Maintenance therapy; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ACNE; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOPENIA; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; NAUSEA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; THROMBOCYTOPENIA; UNITED STATES; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; HEALTH CARE COST; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MORTALITY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 84938744670     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.05.020     Document Type: Article

References (30)

1. Siegel R., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Howlader N., Noone A.M., Krapcho M., Garshell J., Neyman N., Altekruse S.F., Kosary C.L., Yu M., Ruhl J., Tatalovich Z., Cho H., Mariotto A., Lewis D.R., Chen H.S., Feuer E.J., Cronin K.A. SEER cancer statistics review, 1975-2011 2014, Bethesda, MD.
3. Sandler A., et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010, 5(9):1416-1423.
4. Collett D. Modelling survival data in medical research 2003, Chapman & Hall/CRC.
5. Cappuzzo F., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529.
6. Woods B, Bryden P, Peterson P, Boye ME, Winfree KB, Scott DA, et al. Comparative efficacy of first line induction and maintenance treatment pathways in non-small cell lung cancer. J Thoracic Oncol, in development.
7. Santana-Davila R., et al. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of veterans health administration data. J Thorac Oncol 2014, 9(5):702-709.
8. de Castria T.B., et al. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2013, 8:CD560092.
9. Scagliotti G.V., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
10. Sandler A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
11. Paz-Ares L., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012, 13(3):247-255.
12. Niho S., et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 2012, 76(3):362-367.
13. Treat J., et al. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer 2010, 70(3):340-346.
14. Johnson D.H., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22(11):2184-2191.
15. Karve S.J., et al. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. BMC Health Serv Res 2014, 14(1):555.
16. Ramsey S., et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005, 8(5):521-533.
17. Briggs A., Sculpher M.J., Claxton K. Decision modelling for health economic evaluation 2006, Oxford University Press, Oxford.
18. Eddy D.M., et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. Value Health 2012, 15(6):843-850.
19. Caro J.J., et al. Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health 2012, 15(6):796-803.
20. Cleemput I., et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care 2011, 27(1):71-76.
21. Comparative effectiveness research. Health Affairs, October 8, 2010.
22. Neumann P.J., Cohen J.T., Weinstein M.C. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014, 371(9):796-797.
23. ISPOR. Modeling Good Research Practices. 2012 February 19, 2014]; Available from: http://www.ispor.org/workpaper/Modeling-Good-Research-Practices-Overview.asp.
24. Schiller J.H., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002, 346(2):92-98.
25. Perol M., et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012, 30(28):3516-3524.
26. Ciuleanu T., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440.
27. Chastek B., et al. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012, 8(6):75s-80s.
28. Brown T., et al. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2013, 17(31):1-278. 10.3310/hta17310.
29. RedBook, 2013. Truve Health Analyics. Available at: http://www.micromedix.com/redbok.
30. Centers for Medicare and Medicaid Services. 2013. Available at: http://www.cms.com.